8-K: Tonix Pharmaceuticals Announces Positive Phase 1 Results for TNX-1500 in Kidney Transplant Rejection Prevention

Tonix Pharmaceuticals reports positive topline results from a Phase 1 trial of TNX-1500, a next-generation anti-CD40L mAb, supporting its potential for preventing kidney transplant rejection and treating autoimmune diseases.

Summary

• Tonix Pharmaceuticals announced positive topline results from a Phase 1 trial of TNX-1500, an Fc-modified humanized anti-CD40L monoclonal antibody.
• The trial assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous TNX-1500 in healthy participants.
• TNX-1500 at 10 mg/kg and 30 mg/kg blocked both primary and secondary antibody responses to a test antigen.
• Pharmacokinetic data supports monthly dosing at 10 mg/kg or above.
• The company believes TNX-1500 has the potential to prevent organ transplant rejection and improve graft survival with reduced long-term toxicity.
• A total of 26 participants were enrolled in three cohorts (3 mg/kg, 10 mg/kg, and 30 mg/kg, n=2 placebo).
• TNX-1500 was generally well-tolerated with a favorable safety and tolerability profile.
• The mean half-life of TNX-1500 was 19.6 days at 3 mg/kg, 37.8 days at 10 mg/kg, and 33.7 days at 30 mg/kg.
• Tonix plans to discuss these results with the FDA in an End-of-Phase 1 meeting and intends to pursue a Phase 2 study in kidney transplant recipients pending FDA alignment.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results, indicating potential for a new drug candidate. The tone is optimistic and forward-looking, suggesting a positive outlook for the company's pipeline.

Positives

• TNX-1500 demonstrated a favorable safety and tolerability profile in the Phase 1 trial.
• The drug effectively blocked antibody responses at specific doses, indicating its potential for immune modulation.
• Pharmacokinetic data suggests that monthly dosing is feasible.
• The company is moving forward with plans to discuss the results with the FDA and initiate a Phase 2 study.

Negatives

• Aphthous ulcer was the only treatment-emergent adverse event occurring in three or more participants among all TNX-1500 groups; all were rated as mild, possibly related, and resolved in 2-10 days.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include those related to obtaining FDA clearances or approvals, successfully marketing products, clinical development timelines, the need for additional financing, patent protection, and competition.

Future Outlook

The company intends to pursue a Phase 2 study of TNX-1500 in kidney transplant recipients, pending alignment with the FDA.

Management Comments

• Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, stated that there remains a significant need for new agents with improved activity and safety to prevent transplant rejection and treat autoimmune diseases.
• Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals, said that the company is eager to advance TNX-1500 into a Phase 2 efficacy study based on the Phase 1 results.

Industry Context

The development of TNX-1500 addresses the need for safer and more effective anti-CD40L mAb therapies, as first-generation therapies like ruplizumab were limited by an increased risk of thrombosis. Sanofi projects its Fc modified humanized anti CD40L mAb frexalimab will exceed $5 B per year in peak sales.

Comparison to Industry Standards

• First generation anti-CD40L mAb ruplizumab showed activity in modulating autoimmunity and rejection in alloand xeno-transplantation, but was limited by an increased risk of thrombosis.
• TNX-1500 was created by reengineering the Fc region of ruplizumab to preserve activity with improved safety.
• The company believes that the results of this study and prior animal studies indicate that TNX-1500 is potentially best-in-class among anti-CD40L mAbs in development.
• Mass General Hospital just transplanted a genetically engineered pig kidney into a living human and the patient was being treated with anti CD40L mAb tegoprubart from Eledon.

Stakeholder Impact

• Positive results could benefit shareholders through increased stock value.
• Successful development of TNX-1500 could provide a new treatment option for kidney transplant recipients and patients with autoimmune diseases.
• Employees may benefit from the company's progress and potential growth.

Next Steps

• The Company plans to discuss these results with the U.S. Food and Drug Administration (FDA) in an End-of-Phase 1 meeting.
• Pending alignment with the FDA, the Company intends to pursue a Phase 2 study of TNX-1500 in kidney transplant recipients.

Key Dates

Keywords

TNX-1500, anti-CD40L mAb, kidney transplant, autoimmune diseases, Phase 1 trial, Tonix Pharmaceuticals, transplant rejection, pharmacokinetics, pharmacodynamics, safety, tolerability